Peluntamig
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Peluntamig, covering 2025-09-23 to 2025-09-23. Get the full timeline:
Most recent: Clinical Trial Update: A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) [Phase 1, Phase 2]